New research reveals AI bowel cancer test can help patients avoid chemotherapy
This form of cancer was responsible for 1.9 million diagnosed cases worldwide in 2020
Read More
Tag: chemotherapy
Tecentriq, chemo combo shows bladder cancer promise
Tecentriq was the first cancer immunotherapy approved in bladder cancer.
Read More
New Herceptin combo could keep breast cancers at bay
Guiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin is effective at treating women with breast cancer who have no other treatment options.
Read More
Lynparza ASCO success continues with positive ovarian cancer results
The treatment achieved a 72% objective response rate in patients with previously treated germline BRCA1/2-mutated advanced ovarian cancer.
Read More
Trial results show promise for chemo-free future treatment
95% of those treated in the study were found to have a complete remission rate.
Read More
AZ finds lack of lung cancer info available for patients
Available information is often outdated and sometimes inaccurate.
Read More
Maintenance immunotherapy disappoints in SCLC
A trial found that overall survival was not significantly prolonged with combination immunotherapy, or with nivolumab alone.
Read More
Roche’s ipatasertib combo shows early promise in triple-negative breast cancer
The results showed a 73% overall response rate irrespective of PD-L1 status.
Read More
Sprycel combo gets FDA approval
The US Food and Drug Administration has approved the new treatment Sprycel for children one year of age and older, facing a type of blood cancer known as Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) when used in combination with chemotherapy.
Read More
Pfizer, Merck to terminate Phase III Bavencio study
Pfizer and Merck KGaA have announced that they will be terminating the Phase III JAVELIN Ovarian 100 study of Bavencio, as the data did not support the study’s initial hypothesis.
Read More
EU reviewing MSD’s Keytruda/chemo combo
European regulators have kicked off a review of MSD’s Keytruda/pemetrexed combination for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).
Read More
Research backs halving chemo after bowel cancer surgery
Some patients receiving chemotherapy after surgery for bowel cancer might only need three months of treatment rather than the six months currently given, according to new research published in Lancet Oncology.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
